Complete Conference Coverage Archive

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

The median follow-up was 17.6 months at time of interim analysis.

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve survival among patients with metastatic pancreatic adenocarcinoma.

Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer

Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer

The study arms had similar rates of adverse events, with 34.7% of patients in the cisplatin arm and 31.2% of patients in the S-1 arm reporting clinically relevant events.

RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer

RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer

Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy may be a lower-cost alternative, with better post-operative outcomes, to open transthoracic esophagectomy.

Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer

Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer

Previous research suggested that EIPL may improve survival by reducing the number of intraperitoneal-free cancer cells.

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.

Q&A With Martin Dreyling, MD, PhD, on Non-Hodgkin Lymphoma Research Presented at ASH

Q&A With Martin Dreyling, MD, PhD, on Non-Hodgkin Lymphoma Research Presented at ASH

Dr Dreyling, professor of medicine at the University of Munich Hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL.

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.

PET-CT Alone May Not Distinguish Richter Transformation in CLL

PET-CT Alone May Not Distinguish Richter Transformation in CLL

Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.

Axillary Node Management for Breast Cancer: Is Less More?

Axillary Node Management for Breast Cancer: Is Less More?

Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer

This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

CTS5 Predicts Late Distant Recurrence in Hormone Receptor-positive Breast Cancer

CTS5 Predicts Late Distant Recurrence in Hormone Receptor-positive Breast Cancer

The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.

Elotuzumab Meets Primary Endpoint of ORR for Newly Diagnosed Multiple Myeloma

Elotuzumab Meets Primary Endpoint of ORR for Newly Diagnosed Multiple Myeloma

Ninety-five percent of patients received elotuzumab at the increased rate of 5 mL/min without any incidence of IR.

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.

Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3-mutated AML

Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3-mutated AML

At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

Acalabrutinib Yields Promising Response Rates in Relapsed/Refractory Mantle Cell Lymphoma

The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).

Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL

Dasatinib Is Safe and Effective in Philadelphia Chromosome-positive Pediatric ALL

Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.

Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival

Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival

At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.

Are Narrower Margins Safer in Breast-conserving Surgery?

Are Narrower Margins Safer in Breast-conserving Surgery?

Study findings indicate that margin widths of at least 2 mm are associated with reduced risk of ipsilateral breast failure compared with narrower but uninvolved margins.

Exemestane Improves DFS, but Not OS, vs Tamoxifen in Hormone Receptor-positive Breast Cancer

Exemestane Improves DFS, but Not OS, vs Tamoxifen in Hormone Receptor-positive Breast Cancer

Translating these findings into clinical practice will require careful conversations with patients to weigh toxicity and potential benefits for each individual.

Ovarian Function Suppression May Improve Outcomes in Hormone Receptor-positive Breast Cancer

Ovarian Function Suppression May Improve Outcomes in Hormone Receptor-positive Breast Cancer

Further follow-up should help to clarify the safety and benefits of OFS for late breast cancer OS.

COX-2 Inhibition With Celecoxib Does Not Improve Breast Cancer Outcomes

COX-2 Inhibition With Celecoxib Does Not Improve Breast Cancer Outcomes

Elevated COX2 levels are associated with breast cancer progression. COX2 is transcriptionally regulated and enhances the aromatase pathway, especially in estrogen receptor-positive tumors.

Lapatinib May Improve Event-free Survival in HER2+ Breast Cancer

Lapatinib May Improve Event-free Survival in HER2+ Breast Cancer

Patients with stage II to III HER2+ breast cancer underwent tumor biopsy and were then randomly assigned to receive paclitaxel plus trastuzumab alone or with lapatinib for 16 weeks before surgery.

Pathological Complete Response Predicts RFS and DRFS in High-risk Breast Cancer

Pathological Complete Response Predicts RFS and DRFS in High-risk Breast Cancer

The findings support the use of pCR as a primary endpoint for accelerated approval of new drugs when EFS is evaluated in the relevant patient population.

Adding Dual mTOR Inhibitor to Fulvestrant Therapy Does Not Improve PFS in Breast Cancer

Adding Dual mTOR Inhibitor to Fulvestrant Therapy Does Not Improve PFS in Breast Cancer

Patients were randomly assigned to receive fulvestrant, fulvestrant plus continuous daily vistusertib, fulvestrant plus intermittent vistusertib, or fulvestrant plus everolimus.

Does Long Non-coding RNA Increase Late-stage Relapse Risk for HR+ Breast Cancer?

Does Long Non-coding RNA Increase Late-stage Relapse Risk for HR+ Breast Cancer?

Long non-coding RNA bound to ESR-1 might contribute to late-stage HR+ breast cancer relapse, researchers reported.

Five-year Adjuvant Bisphosphonate Not Superior to 2-year Duration for Breast Cancer

Five-year Adjuvant Bisphosphonate Not Superior to 2-year Duration for Breast Cancer

Neither adapted DFS nor OS differed between the groups in multivariate analyses adjusted for patient and tumor variables and chemotherapy.

Genomic Instability Predicts Response to Trastuzumab Plus Lapatinib in ER+ Breast Cancer

Genomic Instability Predicts Response to Trastuzumab Plus Lapatinib in ER+ Breast Cancer

A total of 159 recurrent CNA regions were identified. ERBB2 amplification was associated with high pCR, but the association fell to insignificance after correcting for ERBB2 expression.

Does Radiotherapy Lead to An In Situ Breast Cancer Vaccine?

Does Radiotherapy Lead to An In Situ Breast Cancer Vaccine?

Preclinical studies suggest that radiotherapy's pro-immunogenic effects might improve the antitumor efficacy of immune checkpoint inhibition.

Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma

Predictors and Implications of Rituximab Maintenance Failure in Mantle Cell Lymphoma

Patients who did not reach a first complete remission were twice as likely to fail rituximab maintenance therapy; patients who received autologous stem cell transplant had a decreased failure risk of 69%.

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.

Induction to Deepen Pre-transplant Response Does Not Improve OS in Multiple Myeloma

Induction to Deepen Pre-transplant Response Does Not Improve OS in Multiple Myeloma

Study results suggest that many patients with multiple myeloma should proceed directly to autologous stem cell transplantation after first-line therapy.

Daratumumab Plus Standard Care Doubles PFS in Newly Diagnosed Multiple Myeloma

Daratumumab Plus Standard Care Doubles PFS in Newly Diagnosed Multiple Myeloma

A previous study demonstrated that patients with relapsed MM have a superior PFS and greater depth of response when treated with D-VMP.

Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia

Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.

Q&A With Shaji Kumar, MD: Looking to the Future of Multiple Myeloma Treatment

Q&A With Shaji Kumar, MD: Looking to the Future of Multiple Myeloma Treatment

Cancer Therapy Advisor asked Shaji Kumar, MD, to share his thoughts about where we are now and where we are going regarding promising data and novel approaches for MM treatment.

Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

Previous analysis of the SWOG S0230/POEMS study suggested that goserelin improves survival rates, ovarian function, and raises the likelihood of pregnancy among patients with hormone receptor-negative disease.

Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration

Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration

Researchers pooled results from 3 studies, which included 5114 patients with HER2-positive disease, to determine whether 1-year adjuvant trastuzumab yields the optimal OS, DFS, and rate of cardiac events.

Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer

Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer

Researchers randomly assigned 84 women with HER2-positive breast cancer to receive metformin plus chemotherapy with trastuzumab or chemotherapy with trastuzumab alone.

Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer

Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer

Metastatic TN and hormone receptor-positive disease is incurable and new therapy options are badly needed.

Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival

Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival

Researchers attempted to determine factors associated with DSS after patients with metastatic disease undergo surgical resection.

Olaratumab Monotherapy Benefits Patients With Soft Tissue Sarcoma Post-chemotherapy

Olaratumab Monotherapy Benefits Patients With Soft Tissue Sarcoma Post-chemotherapy

Researchers presented olaratumab monotherapy subgroup results from a phase 2 trial of patients who were previously treated with olaratumab plus doxorubicin or doxorubicin alone.

Vitamin D Supplementation Recommended for Pediatric Patients With Sarcoma

Vitamin D Supplementation Recommended for Pediatric Patients With Sarcoma

Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.

More Than 25% of Patients With Sarcoma Have Anxiety or Depression

More Than 25% of Patients With Sarcoma Have Anxiety or Depression

Researchers at the Seattle Cancer Care Alliance used email and web screening to determine patient quality of life and psychological comorbidities after a sarcoma diagnosis.

Exercise May Mitigate Doxorubicin-related Cardiotoxicity

Exercise May Mitigate Doxorubicin-related Cardiotoxicity

Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.

Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma

Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma

As the disease's location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision-making.

CDX-011 Does Not Benefit Patients With Osteosarcoma

CDX-011 Does Not Benefit Patients With Osteosarcoma

No significant association between GPNBM levels and disease response was found. Due to futility, the researchers did not pursue a second stage of the trial.

BLU-285 May Be Effective for Gastrointestinal Stromal Tumor Regardless of Prior Therapy

BLU-285 May Be Effective for Gastrointestinal Stromal Tumor Regardless of Prior Therapy

Researchers are evaluating whether BLU-285, which is active regardless of resistance-associated mutations, is safe and effective among patients with an imatinib-resistant GIST.

Larotrectinib Shows Promise for Patients With NTRK-fusion Sarcoma

Larotrectinib Shows Promise for Patients With NTRK-fusion Sarcoma

Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.

Cediranib May Be Effective in Alveolar Soft Part Sarcoma

Cediranib May Be Effective in Alveolar Soft Part Sarcoma

In a randomized phase 2 trial, CASPS, researchers enrolled 48 patients with metastatic ASPS that progressed within the preceding 6 months. The primary endpoint was change in tumor size.

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.

Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2

Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2

Although endocrine therapy has been the standard of care for HR+/HER2- breast cancer, cyclin-D and cyclin-dependent kinase (CDK) dysregulation-driven resistance to this treatment occurs at very high rates among patients.

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.

Soft Tissue Sarcoma: Nivolumab With Trabectedin Is Safe and Clinically Active

Soft Tissue Sarcoma: Nivolumab With Trabectedin Is Safe and Clinically Active

Trabectedin, an alkylating agent, removes tumor growth-promoting M2 macrophages, leading to more effective natural killer T cell activity.

Axitinib With Pembrolizumab Promising for Alveolar Soft Part Sarcoma

Axitinib With Pembrolizumab Promising for Alveolar Soft Part Sarcoma

For an ongoing phase 2 trial, researchers are recruiting 30 patients with advanced or metastatic sarcoma to receive the drug combination.

Five-day Preoperative Radiotherapy May Be as Effective as 5-week Course for Sarcoma

Five-day Preoperative Radiotherapy May Be as Effective as 5-week Course for Sarcoma

In an ongoing phase 2 study, researchers are evaluating the safety and efficacy of a 5-day hypofractionated radiotherapy course.

Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

Researchers reported outcomes for patients who underwent a second resection after disease recurrence.

National Cancer Database May Underestimate the Burden of Sarcomas

National Cancer Database May Underestimate the Burden of Sarcomas

Institutional policies determine whether cancers are coded by disease type or organ site, which can lead to miscalculations of the global burden of a particular cancer type.

First-line Osimertinib for EGFR-mutation Positive NSCLC

First-line Osimertinib for EGFR-mutation Positive NSCLC

The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.

The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL

Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL

In order to optimize therapeutic sequencing among patients with CLL, 5 patient aspects must be considered.

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.

Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma

Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma

Four recently approved treatment regimens have demonstrated a PFS benefit for patients with RRMM relative to Rd, but no head-to-head studies have been conducted.

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

For the phase 3 KEYNOTE-024 study, researchers randomly assigned 305 patients with advanced NSCLC of any histological type to 35 cycles of pembrolizumab or 4 to 6 cycles of investigator's choice chemotherapy.

Lung Cancer Treatment in North America: Recent Advances and Future Promises

Lung Cancer Treatment in North America: Recent Advances and Future Promises

At the closing plenary session of WCLC, Paul A. Bunn, Jr, MD, presented a treatment algorithm for lung cancer and discussed where lung cancer research in North America is heading.

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Exon 20 mutations account for 4% to 10% of EGFR mutations in NSCLC and are refractory to EGFR TKIs; there are no targeted therapies available for this patient population.

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

ctDNA next generation sequencing of patient blood samples detected oncogenic drivers in 27 (36%) patients, including HER2 exon 20 insYVMA, BRAF L597Q, and MET exon14 mutations.

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC trial.

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin.

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

For this cross-sectional study, researchers collected the data of 1030 adult patients with advanced NSCLC from medical chart reviews and various patient questionnaires.

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

One-hundred and eight patients received cisplatin plus docetaxel in the control arm; 392 patients in the experimental arm received varying treatments according to BRCA1 mRNA expression levels.

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

Researchers evaluated survival and socioeconomic data from 1,150,722 patients with NSCLC to determine particular factors that may predict OS.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs